• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Arcellx Inc.

    4/17/25 4:26:25 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACLX alert in real time by email
    DEFA14A 1 d929651ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Arcellx, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    C/O TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903 Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Arcellx, Inc. Meeting To Be Held On May 28, 2025 for Stockholders of record as of April 4, 2025 Annual Meeting of Stockholders To order paper materials, use one of the Wednesday, May 28, 2025 1:00 PM, Eastern Time Annual meeting to be held virtually via the internet—please visit www.proxydocs.com/ACLX for following methods. more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/ACLX Internet: For a convenient way to view proxy materials, VOTE, and obtain www.investorelections.com/ACLX directions to attend the meeting go to www.proxydocs.com/ACLX To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Call: 1-866-648-8133 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Email: [email protected] Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the * If requesting material by e-mail, please send a blank e-mail with the internet. 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your If you want to receive a paper or e-mail copy of the proxy material, you must request one. e-mail requesting material. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 16, 2025. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO

    Arcellx, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ALL THE NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSALS 2 AND 3 PROPOSAL 1. To elect three Class III directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified. 1.01 Rami Elghandour 1.02 David Lubner 1.03 Kristin Myers 2. To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the “Executive Compensation” section of the proxy statement. 3. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.

    Get the next $ACLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACLX

    DatePrice TargetRatingAnalyst
    10/8/2024$109.00Buy
    Redburn Atlantic
    9/3/2024Overweight
    Cantor Fitzgerald
    5/31/2024$70.00Overweight
    Piper Sandler
    3/7/2024$81.00Overweight
    Morgan Stanley
    1/4/2024$65.00 → $71.00Buy
    Needham
    12/19/2023$66.00Sector Outperform
    Scotiabank
    10/30/2023Outperform
    TD Cowen
    10/17/2023$52.00Buy
    UBS
    More analyst ratings

    $ACLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Behbahani Ali

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:33:05 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Galligan Andrew H

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:24:21 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Patel Kavita

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:20:49 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Arcellx with a new price target

      Redburn Atlantic initiated coverage of Arcellx with a rating of Buy and set a new price target of $109.00

      10/8/24 7:12:00 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Arcellx

      Cantor Fitzgerald initiated coverage of Arcellx with a rating of Overweight

      9/3/24 7:38:42 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Arcellx with a new price target

      Piper Sandler initiated coverage of Arcellx with a rating of Overweight and set a new price target of $70.00

      5/31/24 7:34:12 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

      Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at 8:30 p.m. CEST (Virtual and In-Person, Milan, Italy) A live webcast of these discussions will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcasts will be archived and available for 3

      5/21/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

      -- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6 months -- -- No delayed neurotoxicities including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel -- -- iMMagine-1 data to be presented during an oral presentation at EHA2025 on Saturday, June 14, 2025 -- -- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies f

      5/14/25 9:30:00 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

      -- iMMagine-1 data accepted for Oral Presentation at EHA -- -- iMMagine-3 study updated to include MRD negativity as a dual primary endpoint -- -- Added two new Board members with commercial and operational expertise -- -- Ended the quarter with $565M in cash, which is expected to fund operations into 2028 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. "Delivering therapies that can positively impact patients' lives is our mission," said Rami Elg

      5/8/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

      -- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market

      3/20/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

      REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters. 

      6/21/22 4:05:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Appoints Michelle Gilson as Chief Financial Officer

      FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.

      5/23/22 4:05:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    SEC Filings

    See more
    • SEC Form 8-K filed by Arcellx Inc.

      8-K - Arcellx, Inc. (0001786205) (Filer)

      5/28/25 4:34:31 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcellx Inc.

      SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)

      5/15/25 4:30:15 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Arcellx Inc.

      8-K - Arcellx, Inc. (0001786205) (Filer)

      5/14/25 10:08:40 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Financials

    Live finance-specific insights

    See more
    • Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

      -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. --   -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --  -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx

      12/9/22 8:15:00 AM ET
      $ACLX
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arcellx Inc.

      SC 13G - Arcellx, Inc. (0001786205) (Subject)

      11/22/24 4:12:28 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

      SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

      11/14/24 4:35:36 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

      SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

      11/14/24 4:31:50 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care